Please login to the form below
Why patient education is important in oncology
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Summary/transcript
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.Dr Ryll believes that educating and communicating these changes in therapy to patients is a challenge. She also points out that patients who are educated and have good knowledge of their disease and treatment, fare better than patients who do not have this knowledge.
Therefore, the Melanoma Patient Network Europe has a heavy focus on education for patients in order to improve outcome. Dr Ryll also highlights the importance of working together with oncologists to achieve this.
Company Details
Brandcast Health
+44 (0)20 7291 5070
Address:
16-17 Little Portland Street
London
W1W 8BP
Latest content on this profile
- Day 2 Round-up from the Giant Health Event
- Robin gives a quick overview of day 2 of the Giant Health Event.
Brandcast Health
- Why patient education is important in oncology
- We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Brandcast Health
- CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
- In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
Brandcast Health
- No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
- The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
Brandcast Health
- FALCON trial of fulvestrant for advanced breast cancer
- The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.
Brandcast Health
- Overview of the GIANT Health Event
- Shafi Ahmed, PhD, FRCS, Director of Virtual Medics and Medical and GIANT Event Co-chair, provides an overview of the GIANT Health Event.
Brandcast Health
- About us
- Contact us
- How to advertise
- Site map
- All content copyright © PMGroup Worldwide Ltd 2017
